tbuckley/cabot-search huggingface dataset:
2005P Prediction of response and identification of mechanisms of resistance to neoadjuvant chemotherapy according to molecular subtypes in muscle-invasive bladder carcinoma
Authors: A. Pinto Marin, L. Trilla, J. Pedregosa Barbas, E. Garcia-Fernandez, A. Wisultschew-Puigdellivol, F. Zambrana Tevar, I. Martínez Salas, P. Gajate, A. Dittmann, R. López-Vacas, L. Kunz, G. Rubio Romero, S. Nieto-Torrero, P. Lalanda-Delgado, A. Pertejo, M.P. González-Peramato, J-A. Fresno-Vara, A. Gámez-Pozo
Journal: Annals of Oncology (2024)
945TiP JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)
Authors: J-P. Machiels, B. Burtness, K.J. Harrington, N.F. Saba, M. Tahara, T. Crossman, L. Hua, A.D. Perera, D.S. Theti, E. Zografos, L.L. Siu
Journal: Annals of Oncology (2024)
846TiP Fixed-duration orelabrutinib plus bendamustine and rituximab versus continuous Bruton Tyrosine Kinase inhibitor (BTKi) in treatment-naïve chronic/small lymphocytic leukemia (CLL/SLL): A multicenter, nonrandomized, pragmatic clinical trial
Authors: L-L. Cao, K-Y. Ding, H. Song, C-C. Wang, Q. Xu, C-Y. Zhou, M-G. Hu, J. Ming, G-L. Wu, D-D. Fan, Y-Y. Feng, X-C. Wang
Journal: Annals of Oncology (2024)
845TiP CNS lymphoma imaging and molecular biomarkers study: CLIMB
Authors: P. Ntellas, S. Li, L. Hobbis, K. Piadel, D. Cunningham, A. Macklin-Doherty, D. El-Sharkawi, S. Iyengar, E. Nicholson, C. Arias, S. Easdale, I. Chau
Journal: Annals of Oncology (2024)
795TiP A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors
Authors: I.L. Ray-Coquard, J.F. Liu, D. O'Malley, A. Oaknin, B. Pothuri, D. Lorusso, R.N. Eskander, S. Westin, N.J. Lakhani, W.B. McKean, T. Koyama, S. Kitano, M.C. Lim, C.A. Gomez-Roca, J.A. Perez Fidalgo, G. Curigliano, M. Campone, B. Sharkey, E. Avsar, C. Friedman
Journal: Annals of Oncology (2024)
1137P Efficacy of LNS8801 in melanoma patients with prior immune-related adverse events from immune-checkpoint inhibitors
Authors: J.V. Cohen, T.K. Garyantes, C. Muller, C.A. Natale, M. Orloff, S. Patel, J. Rodon, A.N. Shoushtari
Journal: Annals of Oncology (2024)
1140TiP Safe stop IPI-NIVO trial: Early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
Authors: J.C. Janssen, B. van Dijk, K. de Joode, M. Aarts, F. Van den Berkmortel, C.U. Blank, M. Boers-Sonderen, F. Van Den Eertwegh, J.W. de Groot, M. Jalving, A. Joosse, A. Huismans, E. Kapiteijn, K.A.T. Naipal, D. Piersma, B. Rikhof, G. Vreugdenhil, H.M. Westgeest, E.E.A.P. Mulder, A.A.M. Van der Veldt
Journal: Annals of Oncology (2024)
2021TiP INTerpath-005: Phase II study of pembrolizumab (pembro) with V940 (mRNA-4157) versus pembro with placebo (pbo) for adjuvant treatment of resected high-risk muscle-invasive urothelial carcinoma (MIUC)
Authors: G.P. Sonpavde, B. Perez Valderrama, K. Chamie, S. Gupta, M. De Santis, R. Meehan, T. Posadas, Y. Ren, A. Bavle, T.B. Powles
Journal: Annals of Oncology (2024)
2009P PUNCH02: Primary results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response (cCR) MIBC patients
Authors: B. Huang, Z. Wang, C. Luo, Y. Wu, J. Lei, L. Chen, J. Chen
Journal: Annals of Oncology (2024)
796TiP Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS)
Authors: J. Kim, J.H. Kim, B. Park, J. Bae, U. Kim, J-Y. KIm, B. You, Y.J. Chang, S-Y. Park, M.C. Lim
Journal: Annals of Oncology (2024)
987TiP First-in-human dose escalation trial of fourth generation chimeric antigen receptor (CAR) T cell therapy (EU307) in patients with glypican-3 (GPC3) positive hepatocellular carcinoma (HCC)
Authors: D-Y. Kim, P.S. Sung, B.H. Kim, J.Y. Jang, H. Park, Y. Choi, Y. Chang
Journal: Annals of Oncology (2024)
1906P ESMO-ESTRO consensus recommendations regarding the safety of combining radiotherapy with targeted agents or immunotherapy
Authors: E. van Aken, D. Martins Branco, D. De Ruysscher, J. Barriuso, L. Castelo-Branco, B. Devnani, A. Gandhi, S.M. O'Cathail, A. Prelaj, C. Belka, F. Lordick, C.A.M. Marijnen, U. Ricardi, M.C. de Jong, G. Pentheroudakis
Journal: Annals of Oncology (2024)
2023TiP A phase I/II study of EG-70 (detalimogene voraplasmid) intravesical monotherapy for patients (pts) with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)
Authors: J. Palou, G. Marcq, G. Steinberg, C. Toscone, J. Sullivan, T. Linback, R. Pruthi, R. Bryce, G. Brown
Journal: Annals of Oncology (2024)
1997P Novel biomarker, ephrinB2 (B2), predicts resistance to treatment and poor overall survival (OS) metastatic urothelial carcinoma (mUC)
Authors: S. Sadeghi, N. Mar, D. Tsao-Wei, I. Siddiqi, D. Freeman, K. Torkko, A. van Bokhoven, T. Flaig, P. Gill, A. Rezazadeh Kalebasty, G.P. Sonpavde, J. Bellmunt
Journal: Annals of Oncology (2024)
1899P Cannabinoids for cancer-associated symptoms: A systematic review and meta-analysis
Authors: I. Creanga-Murariu, I-I. Rezus, R. Karami, A. Rancz, D. Veres, M.A. Engh, M. Obeidat, S. Bunduc, B-I. Tamba, P. Hegyi
Journal: Annals of Oncology (2024)
1239TiP NEO-PIONEER: Neoadjuvant hypofractionated radiotherapy plus tislelizumab with anlotinib followed by adjuvant tislelizumab with anlotinib in patients with resectable non-small cell lung cancer (NSCLC): A phase II trial in progress
Authors: M. Fang, L. Cai, T. Luo, Y. Ji, J. Zeng
Journal: Annals of Oncology (2024)
1908P Grading the evidence for physical activity and all outcomes in cancer survivors: An umbrella review of more than 700 meta-analytic associations
Authors: P. Filis, G. Markozannes, D. Chan, D. Mauri, T. Foukakis, A. Matikas, S. Droufakou, G. Pentheroudakis, K. Tsilidis
Journal: Annals of Oncology (2024)
1138P A prospective study of patients with immune checkpoint inhibitor-induced hepatitis: Management outcome and association with liver injury subtype, immune infiltration, and clinical parameters
Authors: R.B. Holmstroem, A.S. Teisner, M. Sweep, I.M. Noringriis, S. Khan, N.K. Aagaard, P. Nissen Bjerring, R.S. Jurlander, J.E. Jörn, T.J. Monberg, C.D. Vestergaard, J. Stoltenborg Granhøj, P. Stenbøg, K. Bol, G. Jönsson, E. Ellebaek, I.M. Svane
Journal: Annals of Oncology (2024)
1907P Deployment of remote patient monitoring in older patients: A real-world experience from 2419 patients across 58 centres in France and Belgium
Authors: N. Bertrand, T. Grellety, M. Autheman, R. Rivoirard, R. Boulahssass, E.G.C. Brain, L. Mourey, C. Dumas-Bonnetain, P. Caillet, M. Frelaut, B. Beauplet, M. Bringuier, C. Chakiba Brugere, A-L. Couderc, F. Canouï-Poitrine, C. Baldini
Journal: Annals of Oncology (2024)
1994P Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in ≥ second line in metastatic urothelial carcinoma (mUC)
Authors: B.A. McGregor, G.P. Sonpavde, L. Kwak, X. Gao, S. Berg, C. Mantia, X.X. Wei, P. Ravi, M.D. Michaelson, T.K. Choueiri, J. Bellmunt
Journal: Annals of Oncology (2024)
1717TiP CARE1 pragmatic clinical trial: First line randomised study platform to optimize treatment in patients with metastatic renal cell carcinoma
Authors: L. Albiges, C. Suarez Rodriguez, G. Procopio, A. Bex, V. Gruenwald, M. Schmidinger, B. Melichar, G.A. De Velasco Oria, C.D. Bergerot, R. Giles, R. Woodward, A.R. Ferreira, N. Rioux-Leclercq, J. Bonastre, M. Claveau, R. Flippot, B. Escudier, S. Foulon, T.B. Powles
Journal: Annals of Oncology (2024)
1133P Only early adjuvant radiotherapy, particularly of the tumor bed rather than the lymph node region, improves prognosis in Merkel cell carcinoma: Results from the prospective German MCC registry
Authors: J.C. Becker, U. Leiter-Stoppke, A. Gesierich, C. Ulrich, K.C. Kähler, C. Pfoehler, T. Gambichler, I. Wolf, R. Herbst, F. Meier, J.C. Hassel, F. Meiß, P. Mohr, P. Terheyden, C. Zouboulis, A. Stang, W. Galetzka, S. Ugurel-Becker, G.C. Lodde
Journal: Annals of Oncology (2024)
1904P Factors and trends associated with alcohol intake in patients with breast cancer
Authors: S. Rajput, R.A. Vierkant, N. Larson, D.L. Stan, D.M. Mussallem, S.D. Dandre, F.J. Couch, J.E. Olson, C.C.M. O'Sullivan, K.J. Ruddy
Journal: Annals of Oncology (2024)
2016P Evaluation of event-free survival (EFS) as a surrogate endpoint for overall survival (OS) in muscle-invasive bladder cancer (MIBC) following neoadjuvant (NAD) therapy
Authors: C.N. Sternberg, P.J. Squires, Y. Song, A. Wu, Y. Gao, C. Xu, R. Kataria, H. Li
Journal: Annals of Oncology (2024)
1993P A randomized, phase II trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer where cisplatin-based treatment is not an option
Authors: A.A. D'Souza, N. Mar, R. Parikh, M. Parikh, M. Arora, S. Hinton, Y.M. Lyou, J. Ohr, S. Peracha, S. Sadeghi, M. Sulecki, R.A. Thomas, M. Villalona-Calero, P.N. Lara, E. Sharon, M. Krailo, D.I. Quinn
Journal: Annals of Oncology (2024)
2019P Disparities in urothelial carcinoma (UC) drug approval: Contrasting North America and Europe
Authors: J.C. Tapia, J. Gavira, D. Matthews, M. Santoni, M.N. Young, L. Blondel, R. Flippot, R. Frazer, G. Anguera Palacios, J.P. Maroto Rey
Journal: Annals of Oncology (2024)
791P Activity of ERK1/2 inhibitor ASTX029 in patients with gynecological malignancies harboring genomic alterations in the MAPK pathway
Authors: G. Shapiro, J.E. Ang, E. Castanon Alvarez, A.I. Spira, P. Cassier, P. Lorusso, S. Gaillard, H.A. Chen, S. Kummar, M.G. Krebs, R. Plummer, E. Carcereny, E. Meshoulam Nikolaeva, J. Munck, D. Chan, M. Dijkstra, H.N. Keer, E.K. Lee
Journal: Annals of Oncology (2024)
1924P Efficacy and safety of lenvatinib in patients with chemotherapy-naive advanced or recurrent thymic carcinoma: A multicenter retrospective study
Authors: D. Hazama, K. Takagi, G. Saito, R. Tsugitomi, H. Ashinuma, T. Shukuya, H. Gyotoku, S. Sakata, A. Mouri, H. Miwa, Y. Tamura, T. Tokito, Y. Tsukita, Y. Kogure, T. Masuda, H. Tanaka, S. Kubo, T. Suzuki
Journal: Annals of Oncology (2024)
1995P Insights into second-line (2L) systemic treatment (tx) receipt in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany
Authors: G. Niegisch, M. Kearney, J. Krieger, U. Osowski, B. Deiters, U. Maywald, T. Wilke, M-O.J. Grimm
Journal: Annals of Oncology (2024)
2024TiP NETOS: A personalized approach of neoadjuvant therapy, including INCB099280 monotherapy and bladder preservation, for muscle-invasive urothelial bladder carcinoma (MIBC) with ctDNA monitoring
Authors: V. Tateo, A. Cigliola, C. Mercinelli, B.A. Maiorano, M. Moschini, R. Colombo, M. Colecchia, G. Brembilla, A. Briganti, F. Montorsi, A. Necchi
Journal: Annals of Oncology (2024)
62TiP HERIZON-BTC-302: A phase III study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line (1L) treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC)
Authors: T. Macarulla Mercade, J.J. Harding, S. Pant, X. Wu, P. Garfin, T. Okusaka
Journal: Annals of Oncology (2024)
2020TiP SOGUG-NEOWIN: A phase II, open-label, multi-centre trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) and FGFR gene alterations
Authors: Y. Loriot, A. Necchi, S.A. Hussain, G.A. De Velasco Oria
Journal: Annals of Oncology (2024)
1139TiP IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma
Authors: M.O. Butler, R. Weight, R. Haq, A. Javed, S. Chandana, B. Chmielowski, R. Dummer, M.S. Carlino, M. Mckean, J. Moser, S. Chandrasekaran, S. Khan, K.B. Kim, J. Lutzky, M. Shackleton, V.G. Atkinson, D. Beaupre, G.W. Cole, H. Patel, M. Orloff
Journal: Annals of Oncology (2024)
1909TiP Home-based physical exercise during neoadjuvant treatment for early breast cancer patients (HoPEx-Breast): A pragmatic randomised controlled trial
Authors: R.C. Pichel, A. Cavalheiro, L.M.D.C. Soares Miranda, N. Ramalhao, F. Rebelo, J.Q. Coelho, L. Pratas Guerra, H.M. Miranda, M.M. Braga, G. Pinhol, F.F. Goncalves, J.C.D.L. Simões, M.J.P. de Sousa, R.M. Romao, P. Cantista, A.V.D. Araujo, A. Araujo
Journal: Annals of Oncology (2024)
789P Translational study and preliminary clinical trial of WX390 monotherapy in cancers with concurrence of PIK3CA and ARID1A mutations
Authors: J. Li, X. Wu, G. Li, A. Huang, D. Wang, Q. Chen, L. Wang, R. An, Y. Huang, Y. Kang, X. Cheng, B. Li, G. Zhu, F. You, Y. Qi, Y. Li, J. Wang
Journal: Annals of Oncology (2024)
844TiP Orelabrutinib combined with rituximab for the treatment of elderly patients with newly diagnosed non-GCB diffuse large B-cell lymphoma (DLBCL) under the guidance of genetic subtype: A prospective, multicenter, single-arm, response-adaptive clinical study (Origin)
Authors: W. Xie, X. Zheng, D. Zhou, Y. Shi, J. Wang, J. Sun, C. Yang, C. Hu, W. Yu, H. Tong, J. Jin
Journal: Annals of Oncology (2024)
1996P Primary analysis of post-marketing surveillance (PMS) data for avelumab maintenance therapy in patients (pts) with curatively unresectable urothelial carcinoma (UC) in Japan
Authors: E. Kikuchi, M. Nagata, T. Ito, M. Sato, M. Ogi, M. Morita, M. Kajita, H. Nishiyama
Journal: Annals of Oncology (2024)
2003P Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
Authors: M. Sternschuss, K. Whiting, M.Y. Teo, D. Bajorin, R. Kotecha, A.L. Laccetti, H. Xiao, E. Feld, D.J. McHugh, N. Keegan, A. Apollo, C. Owens, S.A. Funt, N.J. Shah, G. Iyer, D.H. Aggen, I. Ostrovnaya, J.E. Rosenberg
Journal: Annals of Oncology (2024)
1534TiP Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic Pancreatic Adenocarcinoma patients-VESPA trial
Authors: A. Budillon, L. Silvestro, M. Reni, M. Milella, G. Tortora, M. Rodriguez, F. Fiore, A. Petrillo, M. De Bellis, E. Cavalcanti, M. Macchini, A. Leone, E. Di Gennaro, E. Passaro, M. Borrelli, M.L. García Bermejo, E. Hewitt, C. Fuchs, D. Giannarelli, A. Avallone
Journal: Annals of Oncology (2024)
2008P Assessing response durability and survival after second-line pembrolizumab in advanced urothelial carcinoma: A multicenter validation of a risk model
Authors: S. Salah, T. Kobayashi, K. Ito, Y. Kita, M. Horani, A. Alshangiti, R. Abu Hijlih, M. Sammour, F. Abuhijla, K. Al-Rabi
Journal: Annals of Oncology (2024)
2013P First preliminary results of artificial intelligence generated treatment recommendations for urothelial cancer based on multidisciplinary cancer conferences from the KITTU project
Authors: G. Duwe, D. Mercier, V. Kauth, K. Moench, M. Junker, J.P. Vesga, W. Seiz, J. Scheele, A. Dengel, A. Haferkamp, T. Höfner
Journal: Annals of Oncology (2024)
2007P Similar genetic profile in early and late-stage urothelial tract cancer suggests that early genomic testing bears the potential of timely personalized treatment in clinical trials
Authors: D.R. Stormoen, K.S. Rohrberg, K.W. Mouw, K. Ørum, Z. Szallasi, M. Rossing, F. Bagger, H. Pappot
Journal: Annals of Oncology (2024)
1998P Preliminary results from a phase I study of T3011, an oncolytic HSV expressing IL-12 and anti-PD-1 antibody, for BCG-failure non-muscle-invasive bladder cancer (NMIBC)
Authors: D. Ye, J. Wu, G. Zhou, K. Wang, R. Yan, X. Chen, X. Jin, W. Fu, J.J. Niu
Journal: Annals of Oncology (2024)
2001P Epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial cancer in France: A non-interventional database study
Authors: F. Joly Lobbedez, M. Roupret, S. Culine, A. Tricotel, E. Casarotto, R. Minacori, T. Strunz-McKendry, K. Karzazi, K. Leyland, M. Vuillet, M-C. Thomas
Journal: Annals of Oncology (2024)
1136P Cosibelimab in advanced cutaneous squamous cell carcinoma (CSCC): Longer-term efficacy and safety results from pivotal study
Authors: E. Muñoz-Couselo, H. Montaudie, M.A. Berciano Guerrero, M.D.C. Alamo De La Gala, J. Charles, G. Quereux, C. Nardin, R. Yaya Tur, S. Dalle, M. Beylot-Barry, R. Ladwa, M. McGrath, D. Brungs, D. Harris, H. Shue, A. Tazbirkova, S.J. Fourie, D.R. Malan, J. Oliviero, P. Clingan
Journal: Annals of Oncology (2024)
2022TiP Stereotactic treatment with neoadjuvant radiotherapy and enfortumab vedotin: A phase I/II study for localized, cisplatin ineligible, muscle invasive bladder cancer (STAR-EV)
Authors: T. Zhang, S. Woldu, Q. Qin, S. Cole, W. Arafat, C. Jiang, J. Wang, K. Courtney, A. DeVilbiss, R. Ploski, R. Hannan, D. Yang, A. Garant, I. Tachibana, K. Gaston, A.Z. Wang, V. Margulis, Y. Lotan, N. Desai
Journal: Annals of Oncology (2024)
1902P Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective
Authors: T. Hijal, H. Dahn, V. Theberge, V. Panet-Raymond, E. Wiebe, I. Kong, D. Rodin, N. Logie, E. Chow, B. Bashir, P. Wright, J-M. Caudrelier, J-M. Bourque, M. Yassa, M. Sauder, J. Claveau, C.H. Avella Bolivar, S. Marchuk, N. Dayeh, J. Cao
Journal: Annals of Oncology (2024)
2010P Trifunctional anti-EpCAM/CD3 bsAb catumaxomab intravesically for high and intermediate risk non muscle invasive bladder cancer (HMR-NMIBC): Interim analysis of a phase I study
Authors: A.A. Antoniewicz, F. Albert, F. Wessels, M. Lenhart, M. Neuberger, P. Ruf, H. Lindhofer, R. Oberneder, M. Kriegmair
Journal: Annals of Oncology (2024)
2014P Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA)
Authors: P. Giannatempo, A. Polymeropoulos, M. Stellato, P. Ambrosini, E. Gusmaroli, C. Cavalli, V. Guadalupi, M. Claps, D. Raggi, A. Rametta, C. Ortega, M. Tucci, S. Buti, S. Pipitone, R. Iacovelli, G. Calareso, A. Alessi, G. Procopio, R. Miceli, A. Necchi
Journal: Annals of Oncology (2024)
2000P Combining whole blood RNA-sequencing (WB-RNA) and circulating tumor DNA (ctDNA) for the early identification of patients (pts) without clinical benefit to immune checkpoint inhibitors (ICI) in metastatic urothelial cancer (mUC)
Authors: S. Van Wilpe, D. Croci, I. te Paske, S.H. Tolmeijer, S. Costa, L. Ciarloni, P. Romero, J. van Ipenburg, L. Kroeze, S. Pavan, I.M. Oving, T.J. Smilde, T. Van Voorthuizen, M. Berends, M. Franken, M. Ligtenberg, S. Hosseinian Ehrensberger, N. Mehra
Journal: Annals of Oncology (2024)
Unravelling the complexities of resistance mechanism in pancreatic cancer: insights from in vitro and ex-vivo model systems
Authors: Giulia Lencioni, Alessandro Gregori, Belen Toledo B, Rita Rebelo, Benoit Immordino, Manoj Amrutkar, Cristina P R Xavier, Anja Kocijančič, Deo Prakash Pandey, Macarena Perán, Justo P Castaño, Naomi Walsh, Elisa Giovannetti
Journal: Seminars in Cancer Biology (2024)

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis and rising global deaths. Late diagnosis, due to absent early symptoms and biomarkers, limits treatment mainly to chemotherapy, which soon encounters resistance. PDAC treatment innovation is hampered by its complex and heterogeneous resistant nature, including mutations in key genes and a stromal-rich, immunosuppressive tumour microenvironment. Recent studies on PDAC resistance stress the need for suitable in vitro and ex vivo models to replicate its complex molecular and microenvironmental landscape. This review summarises advances in these models, which can aid in combating chemoresistance and serve as platforms for discovering new therapeutics. Immortalised cell lines offer homogeneity, unlimited proliferation, and reproducibility, but while many gemcitabine-resistant PDAC cell lines exist, fewer models are available for resistance to other drugs. Organoids from PDAC patients show promise in mimicking tumour heterogeneity and chemosensitivity. Bioreactors, co-culture systems and organotypic slices, incorporating stromal and immune cells, are being developed to understand tumour-stroma interactions and the tumour microenvironment's role in drug resistance. Lastly, another innovative approach is three-dimensional bioprinting, which creates tissue-like structures resembling PDAC architecture, allowing for drug screening. These advanced models can guide researchers in selecting optimal in vitro tests, potentially improving therapeutic strategies and patient outcomes.
Strength of Evidence Underlying the CMS-FDA Parallel Review of Comprehensive Genomic Profiling Tests in the Cancer Setting
Authors: Sydnie Stackland, Dominic Schnabel, Michaela Dinan, Carolyn J Presley, Cary P Gross
Journal: JNCI Journal of the National Cancer Institute (2024)

Abstract Background Although use of comprehensive genomic profiling (CGP) was approved by a novel CMS/FDA parallel review process, the quality of the supporting evidence is unclear. We evaluated the rigor of the peer-reviewed literature cited in the National Coverage Determination Memorandum for the FoundationOne CDx (F1CDx). Methods We identified studies cited in the memorandum. Two independent researchers evaluated each study and applied a modified version of the Fryback and Thornbury hierarchy[1], an established framework for evaluating the efficacy of diagnostic tests. Studies focused on clinical outcomes were then categorized by study design, guided by recommendations from the Center for Medical Technology Policy. Results The sample included 113 scientific studies. The majority (n = 60, 53.1%) used CGP outside the course of clinical care, and there was significant heterogeneity in the cancer types assessed and sequencing depth. We found 8 (7.1%) studies that assessed whether clinical care had changed due to CGP testing, and 38 (33.6%) assessed clinical outcomes. After excluding studies that tested for five or fewer genomic alterations, 25 remained in the clinical outcomes sample: Of these, only one included a comparator group that did not receive CGP testing. Only four studies used F1CDx as the primary genomic test, none of which compared the outcomes of patients who did vs did not receive the F1CDx test. Conclusions The findings indicate gaps in the supporting evidence for broad CGP use in patients with solid tumors. More rigorous studies that assess clinical utility would better inform the approval process for novel diagnostic tests.
572P Tolerance of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34 – FFCD 1402 - ADAGE randomized phase III trial
Authors: T. Aparicio, P-L. Etienne, O. Bouche, E. Barbier, S. Hiret, H. Ammarguellat, R. Desgrippes, J. Martin, V. Guerin Meyer, V. Le Brun-Ly, M. Ben Abdelghani, C. Falandry, J. Turpin, Y. Rinaldi, J. Desrame, R. Darrius, A-L. Villing, C.I. Furtos, C. Lepage, L. Mineur
Journal: Annals of Oncology (2024)
543P Tumor mutational burden (TMB), BRAF status, and C-reactive protein (CRP) predict response to first-line alternating oxaliplatin-based chemotherapy and nivolumab in metastatic microsatellite-stable (MSS) colorectal cancer (CRC)
Authors: A.H. Ree, P.A. Bousquet, H.L. Nilsen, T. Lüders, S. Wang, T. Visnovska, D.L. Bordin, E. Høye, H.M. Hamre, C. Kersten, E. Hofsli, M.G. Guren, H. Sorbye, J.P. Berg, K. Flatmark, S. Meltzer
Journal: Annals of Oncology (2024)
531P Prognostic value of liver metastases, KRAS mutations and race in colorectal cancer patients: A pooled analysis of third-line placebo-controlled trials from the ARCAD database
Authors: T. André, M. Raeisi, Q. Shi, T. Yoshino, J.R. Zalcberg, R.A. Adams, C. Cremolini, A. Grothey, R.J. Mayer, J. Li, B. Chibaudel, A. De Gramont
Journal: Annals of Oncology (2024)